banter and General Discussion, page-17332

@reginaldp

you only have to look at the breathtaking lack of due diligence from two supposedly expert Australian fund managers, revealed in a online broadcast for a popular Australian financial news website , last week, to see why the shares are languishing. In the buy , sell or hold interview , between 9:30-13:00 minute mark , their tone death attitude to recent progress, was amplified by their stupidity in not realising that Mesoblast now had an approved product and had completed a recent placing . Amazingly , one of the interviewees said the shares might double or treble, if they got an approval but now people should wait until the next capital raise . Pure comedy gold , happily regurgitated by an interviewer to incompetent to check the news releases to see how ridiculous their out of date commentary was.
Then, in my opinion , the supportive note from Bell Potter in April , forecast inflated cash burn for the fiscal year to June 2025, when the latest 4C showed the latest reported quarter at $12.6m ! Do these people get paid for this ! The prospect of SG&A rising in the following fiscal year to US$ 20m per quarter is realisticonly because of the number of additional forthcoming clinical trials which will probably be underway. Rapidly expanding recruitment in the pivotal CLBP Phase 3 combined with a Rux refractory adult sr aGVHD (50-60 patients ? ) costing approximately $10m and potentially a confirmatory trial in HFr EF for 300 patients which may well attract continued support from the NIH or most likely a major pharma.
Rux refractory patients represent 40% of the adult market . Mesoblast has through the Kurtzberg EAP already shown the required efficacy required on a very quick 28 day primary endpoint to give shareholders massive confidence that this will be a relatively simple expansion of the label . In fact I would suggest that within about 2 years , based on real world evidence , the FDA will probably allow Ryoncil to be a second line therapy to steroids. If this were to happen , the price point per vial would probably come down but would generate sales in excess of $1bn to Mesoblast !
What an opportunity as we imminently approach a pivotal Type B cardiac meeting in cardiac . Are the shorters completely nuts? Weight of money deployed has been shielding them from the repercussions of recent positive announcements. By continuously shorting , the contrive to show poor technicals in the chart position which exasperates some retail holders into selling or having their stops ripped out . Total manipulation. Timelines have always been the challenge for Mesoblast trying to comply with the treacle of regulatory oversight . However, label expansion ,for a first in class therapy, often marks the most profitable phase in biotech investment . This may well prove to be Mesoblasts greatest ever year . OP

Please do not rely on the facts or opinions contained in the above post when making an investment decision . Do careful due diligence as biotechs are high risk and can show extreme price volatility